Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision

BACKGROUND: There is uncertainty on the benefit of adjuvant chemotherapy in patients with stage II colorectal cancers. The aim of this study is to investigate the combined role of clinical, pathological and molecular parameters to identify those stage II patients who better benefit from adjuvant the...

Descripción completa

Detalles Bibliográficos
Autores principales: Donada, Marisa, Bonin, Serena, Barbazza, Renzo, Pettirosso, Daniel, Stanta, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599045/
https://www.ncbi.nlm.nih.gov/pubmed/23446022
http://dx.doi.org/10.1186/1471-230X-13-36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599045/
https://www.ncbi.nlm.nih.gov/pubmed/23446022
http://dx.doi.org/10.1186/1471-230X-13-36

Ejemplares similares